Atara Biotherapeutics (ATRA) Stock Statistics & Valuation Metrics

Atara Biotherapeutics has a market cap or net worth of ―. The enterprise value is ―.

Atara Biotherapeutics has ― shares outstanding. The number of shares has decreased by -2.65% in one year.

Atara Biotherapeutics’s return on equity (ROE) is 0.88 and return on invested capital (ROIC) is 327.47%.

The current PE Ratio of Atara Biotherapeutics is -1.17. Atara Biotherapeutics’s PEG ratio is 0.01.

In the last 12 months, Atara Biotherapeutics had revenue of 128.94M and earned -85.40M in profits. Earnings per share was -11.41.

In the last 12 months, operating cash flow was -68.72M and capital expenditures -246.00K, giving a free cash flow of -68.96M billion.

Atara Biotherapeutics pays an annual dividend of ―, resulting in a dividend yield of ―

Atara Biotherapeutics upcoming earnings date is May 7, 2025, TBA Not Confirmed.

Atara Biotherapeutics as a current ratio of 0.48, with Debt / Equity ratio of -45.06%

In the past 12 months, Atara Biotherapeutics has paid -12.00K in taxes.

Atara Biotherapeutics EV to EBITDA ratio is -1.38, with an EV/FCF ratio of -1.52.

Atara Biotherapeutics has $42.50M in cash and marketable securities with $0.00 in debt, giving a net cash position of $1.33M billion.

Gross margin is 83.71%, with operating margin of -64.71%, and net profit margin of -66.23%.

The average price target for Atara Biotherapeutics is $8.28, which is 11.43% higher than the current price. The consensus rating is Moderate Buy